![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, October 29, 2009 12:07:02 AM
Another reason to consider early buyout has to do with Biel's distribution capability. Andy W has made it clear that they will need to either license the product or partner with someone if their products take off. And because the market will potentially be huge for humans (as well as pet and livestock applications), and the profit margins are reportedly near 70%, they may already have suitors lined up for these "roles" after the eventual clearances.
In short, Biel has patented a set of products that have some good science and "following" already, especially with the tylenol and "NSAID" story getting worse, and the public looking for more "organic" solutions (non-toxic) in their medical choices.
Don't you think big pharma can see the writing on the wall, and would want to either buy and shelve this competition, or partake of it in their arsenal? (sorry, that's rhetorical).
In any case, given the above, I do not understand why the PPS remains so low... unless they are printing shares.
All IMO
FEATURED Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM
HealthLynked Expands Telemedicine Nationwide • HLYK • Jul 17, 2024 8:00 AM
Peer To Peer Network aka Mobicard™ Launches AI Investor Chatbot Boosting Engagement & Lead Generation on Ihub • PTOP • Jul 15, 2024 8:30 AM
Greenlite Ventures Announces AI Integration into No Limit Platforms • GRNL • Jul 15, 2024 8:00 AM